Alector (NASDAQ:ALEC) Insider Sells $13,790.55 in Stock

Alector, Inc. (NASDAQ:ALEC) insider Grace Wong-Sarad sold 5,165 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.67, for a total value of $13,790.55. Following the completion of the sale, the insider directly owned 109,640 shares in the company, valued at approximately $292,738.80. The trade was a 4.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Grace Wong-Sarad also recently made the following trade(s):

• On Friday, September 4th, Grace Wong-Sarad sold 3,625 shares of Alector stock. The shares were sold at an average price of $2.51, for a total value of $9,098.75.
• On Wednesday, September 2nd, Grace Wong-Sarad sold 656 shares of Alector stock. The stock was sold at an average price of $2.75, for a total value of $1,804.00.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $2.46 on Monday. The business’s 50 day moving average price is $1.91 and its 200-day moving average price is $2.06. Alector, Inc. has a 1 year low of $1.09 and a 1 year high of $3.40. The firm has a market capitalization of $274.68 million, a price-to-earnings ratio of -2.24 and a beta of 0.65. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. The company had revenue of $3.32 million during the quarter, compared to analyst estimates of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. On average, equities research analysts forecast that Alector, Inc. will post -0.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Alector presently has a consensus rating of “Hold” and a consensus target price of $3.62.

Institutional Trading of Alector

Several large investors have recently made changes to their positions in ALEC. Prudential Financial Inc. purchased a new position in Alector in the 2nd quarter valued at $30,000. Hershey Trust Co. grew its holdings in shares of Alector by 100.0% during the fourth quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock worth $32,000 after buying an additional 10,286 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Alector in the fourth quarter valued at about $34,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Alector in the second quarter valued at about $39,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Alector in the fourth quarter worth about $40,000. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.